• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Oaktree Acquisition Corp. III Life Sciences

    6/6/25 4:30:20 PM ET
    $OACC
    Blank Checks
    Finance
    Get the next $OACC alert in real time by email
    8-K
    Units, each consisting of one Class A ordinary share, $0.0001 par value, andone-fifthof one redeemable warrant false 0002029769 0002029769 2025-06-03 2025-06-03 0002029769 us-gaap:CommonClassAMember 2025-06-03 2025-06-03 0002029769 oaccu:ClassaOrdinarySharesMember 2025-06-03 2025-06-03 0002029769 oaccu:RedeemableWarrantsMember 2025-06-03 2025-06-03
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 3, 2025

     

     

    Oaktree Acquisition Corp. III Life Sciences

    (Exact name of registrant as specified in its charter)

     

     

     

    Cayman Islands   001-42383   98-1799512

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    333 South Grand Avenue, 28th Floor  
    Los Angeles, California   90071
    (Address of principal executive offices)   (Zip Code)

    +1 (213) 830-6300

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeemable warrant   OACCU   The Nasdaq Stock Market LLC
    Class A ordinary shares included as part of the units   OACC   The Nasdaq Stock Market LLC
    Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   OACCW   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 3, 2025, Courtney Conigliaro notified the board of directors (the “Board”) of Oaktree Acquisition Corp. III Life Sciences (the “Company”) of her resignation as Chief Financial Officer of the Company. The resignation was effective on June 3, 2025. Ms. Conigliaro’s resignation was not the result of any disagreements with the Board or management of the Company and she is resigning to pursue other professional opportunities.

    On June 3, 2025, the Board appointed Thomas Sweeney as new Chief Financial Officer (principal accounting and principal financial officer) of the Company, effective immediately.

    Mr. Sweeney is a Managing Director within Oaktree Capital Management, L.P.’s (with its affiliates, as applicable, “Oaktree”) finance organization, overseeing various accounting, operations and reporting functions for Oaktree’s performing private credit strategy. Mr. Sweeney also serves as the Controller and Assistant Treasurer for Oaktree’s business development companies, Oaktree Specialty Lending Corporation (NASDAQ: OCSL), Oaktree Strategic Credit Fund and Oaktree Gardens OLP, LLC. Prior to joining Oaktree in 2017, Mr. Sweeney was a Vice President at Fifth Street Asset Management where he oversaw financial reporting for the firm’s publicly traded alternative asset manager and business development companies. Prior to Fifth Street, Mr. Sweeney was an Audit Senior Manager at Deloitte & Touche. Mr. Sweeney is a Certified Public Accountant in the state of New York and holds a B.S. in Accounting from the State University of New York at Binghamton.

    Mr. Sweeney will not be compensated by the Company for his services as a Chief Financial Officer and he has not entered into an employment agreement with the Company. In connection with this appointment, Mr. Sweeney is expected to enter into an Indemnity Agreement and a Letter Agreement with the Company on the same terms as the Indemnity Agreements and Letter Agreements entered into by the directors and officers of the Company at the time of the Company’s initial public offering in October 2024. Other than the foregoing, Mr. Sweeney is not party to any arrangement or understanding with any person pursuant to which he was appointed as an officer, nor is either party to any transactions involving the Company and required to be disclosed under Item 404(a) of Regulation S-K. There are no family relationships between Mr. Sweeney and any of the Company’s directors and executive officers.

    In connection with the appointment of Mr. Sweeney, the Board also confirmed Alvin Shih as the chair of the audit committee of the Board.

     

    2


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: June 6, 2025     OAKTREE ACQUISITION CORP. III LIFE SCIENCES
        By:  

    /s/ Zaid Pardesi

        Name:   Zaid Pardesi
        Title:   Chief Executive Officer

     

    3

    Get the next $OACC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OACC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OACC
    SEC Filings

    View All

    SEC Form 8-K filed by Oaktree Acquisition Corp. III Life Sciences

    8-K - Oaktree Acquisition Corp. III Life Sciences (0002029769) (Filer)

    10/29/25 5:00:34 PM ET
    $OACC
    Blank Checks
    Finance

    SEC Form 8-K filed by Oaktree Acquisition Corp. III Life Sciences

    8-K - Oaktree Acquisition Corp. III Life Sciences (0002029769) (Filer)

    10/17/25 5:20:22 PM ET
    $OACC
    Blank Checks
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Oaktree Acquisition Corp. III Life Sciences

    SCHEDULE 13G/A - Oaktree Acquisition Corp. III Life Sciences (0002029769) (Subject)

    8/12/25 12:12:20 PM ET
    $OACC
    Blank Checks
    Finance

    $OACC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Martinez George Arthur

    3 - Oaktree Acquisition Corp. III Life Sciences (0002029769) (Issuer)

    10/29/25 6:03:09 PM ET
    $OACC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Berry David A

    3 - Oaktree Acquisition Corp. III Life Sciences (0002029769) (Issuer)

    10/22/25 4:30:03 PM ET
    $OACC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Sweeney Thomas

    3 - Oaktree Acquisition Corp. III Life Sciences (0002029769) (Issuer)

    6/16/25 4:38:10 PM ET
    $OACC
    Blank Checks
    Finance